Form 4 for IONS IONIS PHARMACEUTICALS INC

Accepted 2024-02-02 00:00:00 ET · period of report 2024-02-01 · accession 0000874015-24-000109 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2024-02-02	2024-02-01	IONS	Schneider Eugene	EVP, Chf Clinical Develop Ofcr	A - Grant	$0.00	+4,033	51.9K	+8%	$0
	2024-02-02	2024-02-02	IONS	Schneider Eugene	EVP, Chf Clinical Develop Ofcr	S - Sale	$49.59	-2,071	49.8K	-4%	-$102.7K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-02-01	A	A	4,033	$0.00	51,883	D	—	—	(F1) Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the second performance period of the grant to the reporting person reported on January 19, 2022. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 150% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal.
2	Common	Common Stock	2024-02-02	S	D	2,071	$49.59	49,812	D	—	—	(F2) The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Performance restricted Stock Unit Agreement and Grant Notice. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.58 to $49.60 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.